相关实验视频

Updated: Jun 11, 2025

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

针对化疗耐药的三阴性乳腺癌中的表皮生长因子受体通路:一项II期研究

Clinton Yam¹, Miral Patel², Holly A Hill³

¹Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer research communications

|October 2, 2024

概括

将帕尼图穆马布添加到化疗中,显著改善了耐化疗三阴性乳腺癌 (TNBC) 患者的治疗结果. 这种组合疗法显示出更高的病理完整响应率,需要在更大的试验中进一步调查.

科学领域:

在瘤学瘤学.
医学研究医学研究
临床试验临床试验

背景情况:

表皮生长因子受体 (EGFR) 途径的激活与三阴性乳腺癌 (TNBC) 中的化疗耐药性有关.
抑制EGFR通路显示有可能使TNBC细胞对化疗敏感.
在TNBC中EGFR过度表达是常见的,使其成为治疗策略的目标.

研究的目的:

评估帕尼图穆马布,卡博普拉丁和帕克利塔塞尔作为新辅助疗法 (NAT) 的疗效,用于对多克索鲁比和环胺 (AC) 耐药的TNBC.
在这个患者群体中评估病理完整反应 (pCR) /残留癌症负担I类 (RCB-I) 率.
调查组合治疗方案的安全性和耐受性.

主要方法:

一项单臂II期研究招募了患有早期抗AC抗性TNBC的患者.
患者在NAT的第二阶段接受了帕尼图穆马布,卡博普拉丁和帕克利塔克塞尔.
在现有的诊断瘤生物标本上进行了全外体测序.

主要成果:

这项研究招募了43名患有AC抗性TNBC的患者.
组合的pCR/RCB-I率为30.2%,超过了5%的历史控制率.
常见的不良事件包括中性质衰竭和贫血;没有观察到新的安全信号.

结论:

组合疗法达到其主要终点,在抗化疗的TNBC中显示出显著的疗效.
帕尼图穆马布应被视为NAT的组成部分,用于耐化疗TNBC的患者.
建议在更大的随机临床试验中进行进一步评估.

更多相关视频

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...